Ye Xu Selected Research

Moricizine (Moracizine)

6/2022

Moricizine prevents atrial fibrillation by late sodium current inhibition in atrial myocytes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ye Xu Research Topics

Disease

129	Neoplasms (Cancer) 04/2022 - 10/2005
44	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 09/2008
37	Neoplasm Metastasis (Metastasis) 03/2022 - 06/2010
28	Breast Neoplasms (Breast Cancer) 04/2022 - 10/2005
21	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 07/2011
17	Rectal Neoplasms (Rectal Cancer) 03/2022 - 06/2007
16	Colonic Neoplasms (Colon Cancer) 01/2020 - 07/2013
13	Carcinogenesis 04/2022 - 01/2009
8	Inflammation (Inflammations) 01/2022 - 10/2009
8	Myopia 08/2020 - 12/2011
8	Carcinoma (Carcinomatosis) 01/2019 - 12/2003
7	Hypoxia (Hypoxemia) 03/2022 - 05/2013
7	Glioma (Gliomas) 01/2017 - 10/2012
6	Lung Neoplasms (Lung Cancer) 06/2022 - 05/2011
6	Infections 01/2022 - 07/2015
6	Uterine Cervical Neoplasms (Cancer of the Cervix) 06/2021 - 01/2012
5	Wounds and Injuries (Trauma) 01/2022 - 09/2015
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2021 - 05/2011
4	Atrial Fibrillation 06/2022 - 08/2014
4	Hepatocellular Carcinoma (Hepatoma) 04/2022 - 01/2021
4	Tuberculosis (Tuberculoses) 08/2021 - 05/2014
4	Residual Neoplasm 01/2020 - 10/2005
4	Lymphatic Metastasis 11/2019 - 01/2011
4	Leukemia 10/2019 - 07/2008
3	Sepsis (Septicemia) 01/2022 - 01/2021
3	Pathologic Complete Response 01/2020 - 03/2015
3	Astigmatism 01/2020 - 12/2011
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2019 - 01/2017
3	Genomic Instability 06/2018 - 01/2012
3	Adenocarcinoma 01/2017 - 01/2008
3	Alzheimer Disease (Alzheimer's Disease) 02/2016 - 10/2013
3	Ataxia Telangiectasia (Louis Bar Syndrome) 06/2014 - 11/2009
2	Stroke (Strokes) 04/2022 - 08/2021
2	Virus Diseases (Viral Diseases) 01/2022 - 10/2019
2	Colitis 01/2022 - 01/2021
2	Wound Infection (Wound Infections) 01/2022 - 01/2020
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2022 - 01/2014

Drug/Important Bio-Agent (IBA)

41	Proteins (Proteins, Gene)FDA Link 04/2022 - 12/2003
26	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2003
23	Messenger RNA (mRNA)IBA 01/2021 - 02/2006
20	Cisplatin (Platino)FDA LinkGeneric 06/2022 - 06/2011
16	Pharmaceutical PreparationsIBA 03/2022 - 05/2010
11	Long Noncoding RNAIBA 01/2022 - 01/2014
8	Phosphotransferases (Kinase)IBA 01/2022 - 11/2009
8	Transcription Factors (Transcription Factor)IBA 01/2020 - 09/2014
8	DNA (Deoxyribonucleic Acid)IBA 11/2016 - 01/2012
7	RNA (Ribonucleic Acid)IBA 01/2021 - 05/2006
6	Biological ProductsIBA 04/2022 - 04/2012
6	MicroRNAs (MicroRNA)IBA 11/2020 - 11/2015
6	Small Interfering RNA (siRNA)IBA 01/2020 - 01/2012
5	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 08/2016
5	AnthracyclinesIBA 01/2020 - 10/2005
5	Estrogen ReceptorsIBA 05/2019 - 10/2005
5	Progesterone Receptors (Progesterone Receptor)IBA 05/2019 - 10/2005
4	Therapeutic UsesIBA 01/2022 - 08/2017
4	AcetyltransferasesIBA 10/2021 - 11/2009
4	Circular RNAIBA 01/2021 - 12/2019
4	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 01/2013
4	CalciumIBA 01/2021 - 12/2015
4	EnzymesIBA 01/2020 - 01/2017
4	Carrier Proteins (Binding Protein)IBA 01/2020 - 09/2014
4	Capecitabine (Xeloda)FDA Link 01/2019 - 01/2013
3	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2022 - 05/2016
3	AntibodiesIBA 01/2022 - 01/2009
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 01/2020
3	SolutionsIBA 01/2022 - 01/2020
3	Caspase 3 (Caspase-3)IBA 01/2022 - 05/2013
3	ORALIT (ORS)IBA 10/2021 - 03/2015
3	Alkaline PhosphataseIBA 05/2021 - 10/2016
3	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 05/2021 - 11/2016
3	Carcinoembryonic AntigenIBA 05/2021 - 07/2009
3	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 01/2014
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 01/2020
3	CollagenIBA 01/2021 - 01/2019
3	LigandsIBA 01/2020 - 07/2010
3	VaccinesIBA 01/2020 - 07/2015
3	AntioxidantsIBA 10/2019 - 12/2014
3	ErbB Receptors (EGF Receptor)IBA 10/2018 - 03/2009
3	human ERBB2 proteinIBA 05/2017 - 01/2012
3	Tumor Biomarkers (Tumor Markers)IBA 01/2017 - 07/2008
3	Cathepsin DIBA 05/2015 - 09/2010
3	Amyloid (Amyloid Fibrils)IBA 12/2014 - 10/2013
3	Histones (Histone)IBA 06/2014 - 11/2009
2	Cyclin-Dependent Kinase 9IBA 04/2022 - 01/2022
2	5,7- dihydroxy- 6- methoxy- 2- phenylchromen- 4- oneIBA 04/2022 - 01/2022
2	Sirtuin 1IBA 04/2022 - 01/2022
2	AndrogensIBA 03/2022 - 01/2022
2	Interleukin-10 (Interleukin 10)IBA 01/2022 - 11/2016
2	Matrix Metalloproteinases (MMPs)IBA 01/2022 - 06/2013
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 11/2014
2	CytokinesIBA 01/2022 - 10/2019

Therapy/Procedure

28	Therapeutics 04/2022 - 03/2009
20	Drug Therapy (Chemotherapy) 08/2021 - 06/2007
19	Neoadjuvant Therapy 03/2022 - 10/2005
10	Radiotherapy 03/2022 - 06/2007
6	Lasers (Laser) 01/2022 - 11/2015
5	Laser In Situ Keratomileusis (LASIK) 04/2020 - 12/2011
4	Chemoradiotherapy 08/2020 - 01/2013
3	Immunotherapy 01/2021 - 03/2015
3	Photothermal Therapy 03/2020 - 08/2017